Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
about
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
P2860
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Dasatinib, even at low doses, ...... pective study on 114 patients.
@en
Dasatinib, even at low doses, ...... pective study on 114 patients.
@nl
type
label
Dasatinib, even at low doses, ...... pective study on 114 patients.
@en
Dasatinib, even at low doses, ...... pective study on 114 patients.
@nl
prefLabel
Dasatinib, even at low doses, ...... pective study on 114 patients.
@en
Dasatinib, even at low doses, ...... pective study on 114 patients.
@nl
P2093
P50
P356
P1476
Dasatinib, even at low doses, ...... pective study on 114 patients.
@en
P2093
Andrea Camera
Antonella Gozzini
Emilio Usala
Enrica Morra
Enrico Montefusco
Giuseppe Visani
Mario Annunziata
Patrizia Pregno
Pier Paolo Piccaluga
P304
P356
10.1002/AJH.21871
P577
2010-12-01T00:00:00Z